Lloyd L Tran

Lloyd is a scientist with 25-year experience in drug development. He is an inventor with a number of patents in drug therapeutics in the treatment of neurological diseases. Lloyd serves as the chairman and Chief Scientific Officer of Biomed Industries, Inc. Lloyd was the discoverer of NA-831, which has completed the Phase 2 for the treatment of Alzheimer’s Disease. In his early career, he was employed as a research scientist at G.D. Searle, (a subsidiary of Pfizer), and was the director of R&D at Biomed Pharmaceuticals. Lloyd graduated with a BSc (Honours) and completed a PhD in medicinal chemistry at University of Otago and Wellington University of New Zealand.